MAP3K8 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, MAP3K8 activation is also known to be a critical driving factor for drug resistance in various cancers, including melanoma, chronic myeloid leukemia, and thyroid cancer stem cells [36,37,51].